Gastric cancer
Conditions
Interventions
Observation group:None
Sponsors
Sun Yat-sen University Cancer Prevention Center(YNMT)·
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Patient must be >= 18 years old when newly diagnosed with R/M GC/GEJC 2 Patient must have a histologically or cytologically first diagnosis of R/M GC/GEJCbetween Aug 1, 2021 and Jul 31, 2023 (Index date) 3 Patient must have confirmed PD-L1 CPS, TPS or TAP raw score by immunohistochemistry (IHC) using known PD-L1 antibody/assay
Exclusion criteria
Exclusion criteria: 1 Patient with multiple primary cancers 2 Patient has had previous therapy for R/M GC/GEJC 3The PD-L1 status is detected with unknown antibody/assay 4 Patient has known PD-L1 status only with qualitative data or with quantitative data based on other PD-L1 scoring methods except CPS, TPS and TAP 5 Patients has known PD-L1 scores obtained from any specimen other than tumor tissue All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To understand the real-world prevalence of PD-L1 expression ;To describe the real-world 1L treatment pattern by PD-L1 status in R/M GC/GEJC in China; | — |
Secondary
| Measure | Time frame |
|---|---|
| To understand the real-world prevalence of PD-L1 expression by specimen status, testing antibody and staining platform in R/M GC/GEJC in China;To describe the real-world 1L treatment pattern by PD-L1 status in HER2-positive and HER2-negative R/M GC/GEJC in China;To describe the timepoint when PD -L1 testing occurred for R/M GC/GEJC;To explore the correlation between PD-L1 expression and clinicopathological features (e.g., age, gender, primary tumor site, differentiation, Lauren classification, depth of invasion, lymph node metastasis, etc.) in R/M GC/GEJC;To explore the correlation between PD-L1 expression and molecular features (e.g., HER2, EBV, MSI-H, CLDN18.2, FGFR2b, etc.) in R/M GC/GEJC; | — |
Countries
China
Contacts
Public ContactFeng Wang
Sun Yat-sen University Cancer Prevention Center(YNMT)·
Outcome results
None listed